TABLE 1

Patient Characteristics

Patient no.	Age (y)	Dose (kBq/kg)	Baseline PSA	Metastasis^*	GnRH-A/A	Antiandrogen	Abiraterone	Enzalutamide	Docetaxel	Other systemic therapies
1	73	50	224	OSS, BRA	x	x	x	x	x	Ketokonazol, vinorelbine, β-PSMA (¹³¹I)
2	71	50	63	LYM, OSS, HEP	x	x		x	x	Cabazitaxel, estramustine
3	67	50	<0.1	OSS	x	x	x
4	60	50	118	LYM, OSS	x	x		x	x	Cabazitaxel, ²²³Ra
5	70	100	276	LYM, OSS, PUL	x	x	x	x	x	Curevac, thalidomid, celecoxib, DOTATOC
6	53	100	245	LYM, OSS	x
7	58	100	64.7	LYM, OSS, PUL	x	x	x	x	x	β-PSMA (¹³¹I)
8	78	100	420	LYM, OSS	x	x	x	x	x	Cabozantinib
9	79	150	1,153	LYM, OSS	x	x	x	x		Estramustine
10	57	150	744	OSS, HEP, BRA	x	x			x	²²³Ra, β-PSMA (¹⁷⁷Lu)
11	68	200	<0.1	LYM, OSS, PUL, HEP, BRA	x	x	x		x
12	60	200	1,100	LYM, OSS, HEP	x	x	x		x	Sorafenib, TACE (Irinotecan)
13	78	200	2,841	LYM, OSS, HEP	x	x	x	x	x	Tasquinimod
14	63	200	2.8	LYM, OSS, HEP	x	x	x	x

↵* Site of disease according to TNM classification.
GnRH-A/A = previous treatment with gonadotropin-releasing hormone analogs or antagonists; OSS = osseous; BRA = brain; LYM = lymphatic; HEP = hepatic; PUL = lung; TACE = transarterial chemoembolization.